Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardant Health, Inc. (Nasdaq: GH), a precision oncology company based in Palo Alto, California. Through these filings, investors and analysts can review the company’s official disclosures about its capital structure, governance, and key events related to its blood and tissue tests, real-world data activities, and AI analytics in cancer care.
Guardant Health’s common stock is registered on The Nasdaq Global Select Market under the symbol GH, as noted in its Form 8-K filings. The company files current reports on Form 8-K to describe material events, such as public offerings of common stock, private offerings of convertible senior notes, results of stockholder meetings, financial results announcements, and board appointments. These documents outline details like underwriting agreements, convertible note terms, and voting outcomes at annual meetings.
In addition to Form 8-K reports, Guardant Health files annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain more extensive information about its business, risk factors, and financial statements. Proxy statements on Schedule 14A provide further detail on governance matters and executive compensation. Together, these filings offer a regulatory record of how the company finances its operations, manages its corporate governance, and communicates significant developments to the market.
On Stock Titan, Guardant Health’s SEC filings are updated as they are made available through the EDGAR system. AI-powered tools can help summarize long documents, highlight key terms in offerings and note indentures, and make it easier to locate information on topics such as capital raises, voting results, and reporting obligations. This page is intended as a convenient starting point for reviewing Guardant Health’s regulatory disclosures in one place.
Guardant Health insiders reported proposed sales and recent transactions under Form 144. The filing lists restricted stock lapses of 101 shares on
Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including
On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about
The option awards he exercised were originally granted between
Guardant Health, Inc. submitted a Rule 144 notice for the proposed sale of 40,000 common shares on 03/04/2026. The filing lists Charles Schwab & Co., Inc. as the broker and identifies the method as a Broker Payment for Cashless Exercise.
An earlier sale by Kumud Kalia of 2,000 shares on 12/08/2025 for $209,204.00 is reported as securities sold during the past three months.
Guardant Health director Steve E. Krognes reported the vesting and conversion of restricted stock units into common shares. On August 9, 2022 he received a restricted stock unit award that began vesting June 30, 2023, with 25% vesting then and the remaining 75% vesting in equal monthly installments over three years. On February 28, 2026, 154 restricted stock units vested and were converted at no cost into 154 shares of Guardant Health common stock. After these transactions, he directly held 618 restricted stock units and 19,053 shares of common stock.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.
Guardant Health, Inc. files its annual report describing a precision oncology business built around blood and tissue tests, real‑world data and AI analytics to manage cancer across screening, therapy selection and recurrence monitoring. Key products include Guardant360 liquid and tissue tests, Guardant Reveal for minimal residual disease and therapy response, and the Shield blood test for colorectal cancer screening.
The company highlights FDA approvals for Guardant360 CDx and Shield, Medicare coverage for several assays, and expanding global partnerships in Europe and Asia to run its technology locally. Its Smart Platform integrates genomic and epigenomic data to power multiple tests and biopharma offerings. As of the most recent reference dates, non‑affiliate equity market value was about $6.2 billion and common shares outstanding were 131,170,441.
Guardant Health, Inc. reported strong growth for the fourth quarter and full year 2025 while still operating at a sizeable loss. Fourth quarter revenue rose 39% to
For 2025 as a whole, revenue grew 33% to
Free cash flow burn improved to
Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported a routine equity compensation transaction. On February 15, 2026, he exercised or converted 250 Restricted Stock Units at $0 into 250 shares of Guardant Health common stock.
Following this derivative conversion, Musa directly holds 8,493 shares of common stock and 3,248 Restricted Stock Units. The RSUs were part of an award granted on March 6, 2023 that vests over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years.
Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.
The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.